ÂÜÀòÂÒÂ×

Niklas Axelsson is an experienced finance professional with a strong background in leadership roles across various industries, particularly in the pharmaceutical sector. Currently serving as Chief Financial Officer at Sprint Bioscience since October 2024, Niklas previously held the position of Group CFO at Etac Group. A significant tenure at AstraZeneca from 2004 to 2023 included roles such as CFO for Middle East and Africa, Head of Export for International, and Finance Director for Global Product & Portfolio Strategy, with responsibilities encompassing financial planning, compliance, and strategic initiatives. Prior to AstraZeneca, Niklas worked with Bombardier Transportation and Danske Bank, focusing on corporate finance and M&A advisory services. Niklas holds a Master of Science degree in Business Administration from the Stockholm School of Economics.